Gyroscope Theraputics secures £50.4m Series B financing
Syncona and Cambridge Innovation Capital will contribute £48 million and £2.4 million, respectively.
Read More
Tag: dry age-related macular degeneration
First patient dosed in Gyroscope Therapeutics’ AMD study
Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
